RARE DISEASE
Marfan syndrome
Marfan syndrome
Marfan syndrome
Synonyms: MFS
Synonyms: MFS
Synonyms: MFS
Drug discovery
3
drugs
With orphan designations
Overview
Marfan syndrome is an autosomal dominant connective tissue disorder caused by fibrillin-1 gene mutations, leading to cardiovascular, skeletal, ocular, and vascular manifestations. Key features include aortic root dilation, lens dislocation, and disproportionate skeletal growth. Complications such as aortic dissection, mitral valve prolapse, and retinal detachment drive morbidity and mortality. Management involves beta-blockers, angiotensin receptor blockers, prophylactic aortic surgery (at 4.5–5 cm), and multidisciplinary monitoring [1][6][11].
Therapies
Pharmacologic: Beta-blockers (atenolol) or ARBs (losartan) to reduce aortic stress [3][10][16].
Surgical: Prophylactic aortic root replacement at 4.5–5 cm; valve-sparing techniques preferred [6][11][17].
Multidisciplinary care: Annual cardiac imaging, ophthalmologic exams, and orthopedic/physiotherapy interventions [8][16].
Categories: rare bone diseases, rare circulatory system diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare ophthalmic disorders, rare surgical thoracic diseases, rare systemic and rheumatological diseases
Research Papers
1,632 drug discovery papers about Marfan syndrome, with 3 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,632 drug discovery papers about Marfan syndrome, with 3 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-03 | Lymphatic therapies open the valve in Marfan syndrome.
Myxomatous degeneration of the mitral valve (MDMV) is a common cardiovascular manifestation of Marfan syndrome (MFS), yet the role of lymphatic vessels in the disease progression remains unknown. In this Commentary, we discuss the study by Tan, Kume, and colleagues, which identifies defective lymphangiogenesis as a previously unrecognized driver of MDMV. Their work demonstrates that impaired lymphatic development and drainage promote valve inflammation through reduced ZFP36-mediated antiinflammatory signaling, whereas restoration of lymphatic function or pharmacological activation of ZFP36 with the FDA-approved drug FTY720 ameliorates disease progression. These findings establish lymphatic vessels as critical regulators of mitral valve homeostasis and support exploration of lymphatic-targeted therapeutic opportunities for MFS-associated valvular disease.
2026-07-17 | Genetic Bone Diseases: A Scoping Review of Pathology, Symptoms, Diagnosis, Treatment, and New Horizons.
Genetic bone diseases are a rare group of afflictions suffered by the general population. However, their rarity should not diminish research efforts to help patients understand and treat their diseases. This review summarizes the pathology, symptoms, diagnosis, and treatment insight into six well-known genetic bone diseases. Only six bone diseases are included due to the relatively low prevalence of them as whole limiting our scope to ensure accurate information and attention is provided for each disease individually. A literature search of PubMed is conducted, including studies published within the past five years (January 2020-December 2025). Thirty-six studies met inclusion criteria, and no significant risk of bias is identified among the selected articles. Study findings are synthesized into disease overview, clinical and radiographic features, and diagnostic and treatment approaches. Actively developing or novel therapies relevant to each disease are also included. These treatments include: fresolimumab for osteogenesis imperfecta, small interfering ribonucleic acid (RNA) therapy for Osteopetrosis, denosumab for Paget's disease of bone, vosoritide/recifercept/infigratinib for achondroplasia, mesenchymal stem cell therapy for craniosynostosis, and combination losartan and atenolol therapy for Marfan syndrome. These treatments are generally more recently acknowledged in literature and are either actively undergoing research or require further research to determine their efficacy.
2026-07-13 | Sex-Dependent Vascular Responses to Atorvastatin Across Multiple Arterial Beds in a Mouse Model of Marfan Syndrome.
Marfan syndrome (MFS) is characterized by progressive aortic aneurysm formation resulting from mutations in the fibrillin-1 (Fbn1) gene. Although the thoracic aorta is the primary site of pathology, accumulating evidence indicates that vascular dysfunction in MFS extends beyond the aorta to involve multiple arterial beds. Statins have been shown to attenuate aneurysm progression in experimental models of MFS; however, their effects on systemic vascular remodeling and arterial stiffness outside the aorta remain poorly characterized. In this study, we investigated the impact of chronic atorvastatin therapy on vascular structure and hemodynamic function across multiple vascular beds in the Fbn1^C1041G/+^ mouse model of MFS. Male and female control and MFS mice received drinking water with or without atorvastatin (1 g/kg/day) from 4 weeks to 6 months of age, enabling the effects of atorvastatin to be assessed in both healthy and MFS arteries. High-frequency ultrasound imaging was used to assess vascular parameters in the aorta, left common carotid artery (LCCA), and posterior cerebral artery (PCA). Atorvastatin treatment significantly attenuated aortic root dilation in both male and female MFS mice and reduced aortic pulse wave velocity (PWV), indicating improved arterial compliance. In the carotid circulation, atorvastatin significantly reduced LCCA wall thickness and carotid PWV, although carotid wall strain did not improve. Atorvastatin raised both systolic and diastolic blood pressure in male and female MFS mice relative to untreated MFS animals, reaching levels not significantly different from untreated controls in both sexes, while having little effect in healthy controls apart from a rise in female diastolic pressure. In the posterior cerebral artery, peak systolic velocity, a hemodynamic index rather than a direct measure of perfusion, showed similarly sex-dependent changes, increasing in female MFS mice but decreasing further in males after atorvastatin. Collectively, these findings demonstrate that atorvastatin exerts systemic but heterogeneous vascular effects in MFS, improving arterial stiffness and structural remodeling across multiple arterial beds while producing sex-specific hemodynamic responses that warrant further investigation.
2026-07-07 | Fibronectin-induced overactivation of αVβ3-PI3K-PIP3-PDK1-ILK signaling drives aortic disease in Marfan syndrome.
Thoracic aortic aneurysms and dissections (TAAD), a life-threatening complication of Marfan syndrome (MFS), lack curative therapies. Our previous studies revealed that versican accumulation drives MFS aortopathy through AKT-NO pathway overactivation, but the upstream mechanisms remained unclear. Here, we show that versican-driven fibronectin (FN) accumulation activates an αVβ3-PI3K-PIP3-PDK1-ILK signaling cascade leading to AKT-NOS2 upregulation and aortic disease. FN accumulates in aortas of MFS patients and mice of both sexes and correlates with increased αVβ3 integrin and ILK expression. Disrupting FN assembly or inhibiting αVβ3, PI3K, PIP3, PDK1 or ILK prevents FN-induced AKT activation and NOS2 upregulation, restores vascular contractility, and limits aortic dilation in MFS mice. Inhibition of ILK or PDK1, aortic silencing of Ilk, or smooth muscle-specific deletion of Ilk reverses or prevents aortic growth. Together, these findings define a mechanistically integrated FN-αVβ3-PI3K-PIP3-PDK1-ILK-AKT-NOS2 signaling cascade in MFS and support its causative role in human TAAD, highlighting its components as potential targets for therapeutic intervention.
2026-07-04 | Marfan Syndrome: Molecular Basis, Clinical Spectrum, Diagnosis, and Management- A Comprehensive Review
Marfan syndrome (MFS) is a hereditary connective tissue disorder primarily caused by mutations in the FBN1 gene, leading to abnormalities in extracellular microfibril formation and dysregulation of transforming growth factor-beta (TGF-β) signaling. The disorder exhibits autosomal dominant inheritance and presents with significant clinical variability, affecting the cardiovascular, skeletal, and ocular systems. Among these, cardiovascular complications such as aortic root dilation, aneurysm, and dissection represent the most life-threatening manifestations. Advances in diagnostic approaches, particularly the revised Ghent criteria, have improved diagnostic accuracy by integrating clinical features, imaging findings, and genetic testing. Imaging modalities such as echocardiography, magnetic resonance imaging, and computed tomography play a critical role in early detection and monitoring of disease progression. Genetic testing further enhances diagnostic precision, especially in atypical cases. Management strategies focus on preventing complications and improving survival. Pharmacological treatments, including beta-blockers and angiotensin receptor blockers, reduce hemodynamic stress and modulate TGF-β signaling. Surgical interventions, particularly prophylactic aortic root replacement, are essential in high-risk patients. A multidisciplinary approach involving cardiology, genetics, ophthalmology, and orthopedics is crucial for optimal patient care. Emerging diagnostic tools such as next-generation sequencing and biomarker-based assessments, along with novel therapeutic strategies including gene therapy and targeted molecular treatments, hold promise for future disease management. Continued research into the molecular mechanisms of MFS is essential to transition from symptomatic treatment to disease-modifying therapies and to further improve patient outcomes.
2026-08-03 | Lymphatic therapies open the valve in Marfan syndrome.
Myxomatous degeneration of the mitral valve (MDMV) is a common cardiovascular manifestation of Marfan syndrome (MFS), yet the role of lymphatic vessels in the disease progression remains unknown. In this Commentary, we discuss the study by Tan, Kume, and colleagues, which identifies defective lymphangiogenesis as a previously unrecognized driver of MDMV. Their work demonstrates that impaired lymphatic development and drainage promote valve inflammation through reduced ZFP36-mediated antiinflammatory signaling, whereas restoration of lymphatic function or pharmacological activation of ZFP36 with the FDA-approved drug FTY720 ameliorates disease progression. These findings establish lymphatic vessels as critical regulators of mitral valve homeostasis and support exploration of lymphatic-targeted therapeutic opportunities for MFS-associated valvular disease.
2026-07-17 | Genetic Bone Diseases: A Scoping Review of Pathology, Symptoms, Diagnosis, Treatment, and New Horizons.
Genetic bone diseases are a rare group of afflictions suffered by the general population. However, their rarity should not diminish research efforts to help patients understand and treat their diseases. This review summarizes the pathology, symptoms, diagnosis, and treatment insight into six well-known genetic bone diseases. Only six bone diseases are included due to the relatively low prevalence of them as whole limiting our scope to ensure accurate information and attention is provided for each disease individually. A literature search of PubMed is conducted, including studies published within the past five years (January 2020-December 2025). Thirty-six studies met inclusion criteria, and no significant risk of bias is identified among the selected articles. Study findings are synthesized into disease overview, clinical and radiographic features, and diagnostic and treatment approaches. Actively developing or novel therapies relevant to each disease are also included. These treatments include: fresolimumab for osteogenesis imperfecta, small interfering ribonucleic acid (RNA) therapy for Osteopetrosis, denosumab for Paget's disease of bone, vosoritide/recifercept/infigratinib for achondroplasia, mesenchymal stem cell therapy for craniosynostosis, and combination losartan and atenolol therapy for Marfan syndrome. These treatments are generally more recently acknowledged in literature and are either actively undergoing research or require further research to determine their efficacy.
2026-07-13 | Sex-Dependent Vascular Responses to Atorvastatin Across Multiple Arterial Beds in a Mouse Model of Marfan Syndrome.
Marfan syndrome (MFS) is characterized by progressive aortic aneurysm formation resulting from mutations in the fibrillin-1 (Fbn1) gene. Although the thoracic aorta is the primary site of pathology, accumulating evidence indicates that vascular dysfunction in MFS extends beyond the aorta to involve multiple arterial beds. Statins have been shown to attenuate aneurysm progression in experimental models of MFS; however, their effects on systemic vascular remodeling and arterial stiffness outside the aorta remain poorly characterized. In this study, we investigated the impact of chronic atorvastatin therapy on vascular structure and hemodynamic function across multiple vascular beds in the Fbn1^C1041G/+^ mouse model of MFS. Male and female control and MFS mice received drinking water with or without atorvastatin (1 g/kg/day) from 4 weeks to 6 months of age, enabling the effects of atorvastatin to be assessed in both healthy and MFS arteries. High-frequency ultrasound imaging was used to assess vascular parameters in the aorta, left common carotid artery (LCCA), and posterior cerebral artery (PCA). Atorvastatin treatment significantly attenuated aortic root dilation in both male and female MFS mice and reduced aortic pulse wave velocity (PWV), indicating improved arterial compliance. In the carotid circulation, atorvastatin significantly reduced LCCA wall thickness and carotid PWV, although carotid wall strain did not improve. Atorvastatin raised both systolic and diastolic blood pressure in male and female MFS mice relative to untreated MFS animals, reaching levels not significantly different from untreated controls in both sexes, while having little effect in healthy controls apart from a rise in female diastolic pressure. In the posterior cerebral artery, peak systolic velocity, a hemodynamic index rather than a direct measure of perfusion, showed similarly sex-dependent changes, increasing in female MFS mice but decreasing further in males after atorvastatin. Collectively, these findings demonstrate that atorvastatin exerts systemic but heterogeneous vascular effects in MFS, improving arterial stiffness and structural remodeling across multiple arterial beds while producing sex-specific hemodynamic responses that warrant further investigation.
2026-07-07 | Fibronectin-induced overactivation of αVβ3-PI3K-PIP3-PDK1-ILK signaling drives aortic disease in Marfan syndrome.
Thoracic aortic aneurysms and dissections (TAAD), a life-threatening complication of Marfan syndrome (MFS), lack curative therapies. Our previous studies revealed that versican accumulation drives MFS aortopathy through AKT-NO pathway overactivation, but the upstream mechanisms remained unclear. Here, we show that versican-driven fibronectin (FN) accumulation activates an αVβ3-PI3K-PIP3-PDK1-ILK signaling cascade leading to AKT-NOS2 upregulation and aortic disease. FN accumulates in aortas of MFS patients and mice of both sexes and correlates with increased αVβ3 integrin and ILK expression. Disrupting FN assembly or inhibiting αVβ3, PI3K, PIP3, PDK1 or ILK prevents FN-induced AKT activation and NOS2 upregulation, restores vascular contractility, and limits aortic dilation in MFS mice. Inhibition of ILK or PDK1, aortic silencing of Ilk, or smooth muscle-specific deletion of Ilk reverses or prevents aortic growth. Together, these findings define a mechanistically integrated FN-αVβ3-PI3K-PIP3-PDK1-ILK-AKT-NOS2 signaling cascade in MFS and support its causative role in human TAAD, highlighting its components as potential targets for therapeutic intervention.
2026-07-04 | Marfan Syndrome: Molecular Basis, Clinical Spectrum, Diagnosis, and Management- A Comprehensive Review
Marfan syndrome (MFS) is a hereditary connective tissue disorder primarily caused by mutations in the FBN1 gene, leading to abnormalities in extracellular microfibril formation and dysregulation of transforming growth factor-beta (TGF-β) signaling. The disorder exhibits autosomal dominant inheritance and presents with significant clinical variability, affecting the cardiovascular, skeletal, and ocular systems. Among these, cardiovascular complications such as aortic root dilation, aneurysm, and dissection represent the most life-threatening manifestations. Advances in diagnostic approaches, particularly the revised Ghent criteria, have improved diagnostic accuracy by integrating clinical features, imaging findings, and genetic testing. Imaging modalities such as echocardiography, magnetic resonance imaging, and computed tomography play a critical role in early detection and monitoring of disease progression. Genetic testing further enhances diagnostic precision, especially in atypical cases. Management strategies focus on preventing complications and improving survival. Pharmacological treatments, including beta-blockers and angiotensin receptor blockers, reduce hemodynamic stress and modulate TGF-β signaling. Surgical interventions, particularly prophylactic aortic root replacement, are essential in high-risk patients. A multidisciplinary approach involving cardiology, genetics, ophthalmology, and orthopedics is crucial for optimal patient care. Emerging diagnostic tools such as next-generation sequencing and biomarker-based assessments, along with novel therapeutic strategies including gene therapy and targeted molecular treatments, hold promise for future disease management. Continued research into the molecular mechanisms of MFS is essential to transition from symptomatic treatment to disease-modifying therapies and to further improve patient outcomes.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
3 orphan drug designations for Marfan syndrome.
3 orphan drug designations for Marfan syndrome.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
enzastaurin | small molecules | FDA | 2025-04-14 | — | Aytu BioPharma, Inc. |
Allopurinol | small molecules | EMA | 2025-03-25 | — | Consorcio Centro De Investigacion Biomedica En Red |
losartan | small molecules | FDA | 2011-12-12 | — | National Marfan Foundation |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.